Estrogen withdrawal, increased breast cancer risk and the KRAS-variant

References

• Cipollini M, Landi S, Gemignani F. MicroRNA binding site polymorphisms as biomarkers in cancer management and research. Pharmacogenomics Pers Med 2014; 7:173-191; PMID:25114582
   PubMedGoogle Scholar
• Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 2008; 68:8535-8540; PMID:18922928; http://dx.doi.org/10.1158/0008-5472.CAN-08-2129
   PubMed Web of Science ®Google Scholar
• Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, et al. A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 2011; 12:377-386; PMID:21435948; http://dx.doi.org/10.1016/S1470-2045(11)70044-4
   PubMed Web of Science ®Google Scholar
• Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 2010; 15:6509-6515; PMID: 20647319; http://dx.doi.org/10.1158/0008-5472.CAN-10-0689
   PubMed Web of Science ®Google Scholar
• Ratner E, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2012; 31:4559-4566; PMID:22139083; http://dx.doi.org/10.1038/onc.2011.539
   PubMed Web of Science ®Google Scholar
• Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, et al. A KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLos One 2012; 7:e37891; PMID:22662244; http://dx.doi.org/10.1371/journal.pone.0037891
   PubMed Web of Science ®Google Scholar
• Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, et al. A 3′UTR KRAS variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2014; 25:2230-6.
   Google Scholar
• Saridaki Z, Weidhaas JB, Lenz H-J, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, et al. A let-7 microRNA-binding site polymophism is KRAS predicts improved outcome in metastatic colorectal cancer (mCRC) patients treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res 2014; 20:4499-4510; PMID:25183481; http://dx.doi.org/10.1158/1078-0432.CCR-14-0348
   PubMed Web of Science ®Google Scholar
• Weidhaas J, Kim ES, Herbst RS, Yu J, Slack F, Blumenschein GR, Tsao AS, Wistuba II, Lee JJ, Papadimitrakopoulou V, et al. The KRAS-variant and treatment response in BATTLE-1. J Clin Oncol 2014; 32(9S); abstr 8135
   Google Scholar
• Levi F, Randimbison L, Rafael B-M, Manuela M-C, Vecchia CL. Second primary cancers in the Vaud and Neuchatel Cancer Registries. Eur J Cancer Prev 2015; 24:150-4; PMID:25397586
   PubMed Web of Science ®Google Scholar
• Bhatia S. Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors. Cancer 2014; 121:648-63; PMID:25355167; http://dx.doi.org/10.1002/cncr.29096
   PubMed Web of Science ®Google Scholar
• Howe HL, Weinstein R, Alvi R, Kohler B, Ellison JH. Women with multiple primary breast cancers diagnosed within a five year period, 1994–1998. Breast Cancer Res Treat 2005; 90:223-232; PMID:15830135; http://dx.doi.org/10.1007/s10549-004-4258-4
   PubMed Web of Science ®Google Scholar
• Raymond JS, Hogue CJR. Multiple primary tumours in women following breast cancer, 1973–2000. Br J Cancer 2006; 94:1745-1750; PMID:16721370
   PubMed Web of Science ®Google Scholar
• Marcu LG, Santos A, Bezak E. Risk of second primary cancer after breast cancer treatment. Eur J Cancer Care 2014; 23:51-64; PMID:23947545; http://dx.doi.org/10.1111/ecc.12109
   PubMed Web of Science ®Google Scholar
• Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 2009; 101:1058-1065; PMID:19590058; http://dx.doi.org/10.1093/jnci/djp181
   PubMedGoogle Scholar
• Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 1999; 8:855-861; PMID:10548312
   PubMed Web of Science ®Google Scholar
• Narod SA. Bilateral breast cancers. Nat Rev Clin Oncol 2014; 11:157-166; PMID:24492834; http://dx.doi.org/10.1038/nrclinonc.2014.3
   PubMed Web of Science ®Google Scholar
• Brooks JD, John EM, Mellemkjær L, Reiner AS, Malone KE, Lynch CF, Figueiredo JC, Haile RW, Shore RE; WECARE Study Collaborative Group, et al. Body mass index and risk of second primary breast cancer: The WECARE Study. Breast Cancer Res Treat 2012; 131:571-580; PMID:21892703; http://dx.doi.org/10.1007/s10549-011-1743-4
   PubMed Web of Science ®Google Scholar
• Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjær L, Malone KE, Knight JA, Capanu M, Teraoka SN, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the women's environmental cancer and radiation epidemiology study. J Clin Oncol 2013; 31:433-439; PMID:23269995; http://dx.doi.org/10.1200/JCO.2012.43.2013
   PubMed Web of Science ®Google Scholar
• Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010; 28:2404-2410; PMID:20368571; http://dx.doi.org/10.1200/JCO.2009.24.2495
   PubMed Web of Science ®Google Scholar
• Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, Russell NS, van't Veer LJ. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 2004; 83:91-93; PMID:14997059; http://dx.doi.org/10.1023/B:BREA.0000010697.49896.03
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S, Davies C, Evans V, Godwin J, Gray R, McGale P, Peto R, Wang Y, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717; PMID:15894097; http://dx.doi.org/10.1016/S0140-6736(05)71056-4
   PubMed Web of Science ®Google Scholar
• Alkner S, Bendahl PO, Ferno M, Nordenskjold B, Ryden L. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Eur J Cancer 2009; 45:2496-2502; PMID:19535242; http://dx.doi.org/10.1016/j.ejca.2009.05.022
   PubMed Web of Science ®Google Scholar
• Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004; 4:CD002748; PMID:15495033
   PubMedGoogle Scholar
• Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: A review of the literature. Breast Cancer Res Treat 2014; 144:1-10; PMID:24477977; http://dx.doi.org/10.1007/s10549-014-2852-7
   PubMed Web of Science ®Google Scholar
• Liu S, Lin YC. Transofrmation of MCF-10A human breast epithelial cells by zeronal and estrodial-17β. Breast J 2004; 10:514-521; PMID:15569208; http://dx.doi.org/10.1111/j.1075-122X.2004.21410.x
   PubMedGoogle Scholar
• Wang J, Gildea JJ, Yue W. Aromatase overexpression induces malignant changes in estrogen receptor α negative MDF-10A cells. Oncogene 2013; 32:5233-5240; PMID:23178495; http://dx.doi.org/10.1038/onc.2012.558
   PubMed Web of Science ®Google Scholar
• Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362:419-427; PMID:12927427; http://dx.doi.org/10.1016/S0140-6736(03)14596-5
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Manson JE, Anderson GL. Estrogen plus progestin and breast cancer indicence and mortality in the women's health initiative observational study. JNCI 2013; 105:526-535; PMID:23543779; http://dx.doi.org/10.1093/jnci/djt043
   PubMed Web of Science ®Google Scholar
• Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer 2009; 115:936-945; PMID:19156895; http://dx.doi.org/10.1002/cncr.24101
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712; PMID:15082697; http://dx.doi.org/10.1001/jama.291.14.1701
   PubMed Web of Science ®Google Scholar
• Lee L, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, et al. The KRAS-variant and miRNA expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLos One 2014; 9(4):e94167; PMID:24732316; http://dx.doi.org/10.1371/journal.pone.0094167
   PubMed Web of Science ®Google Scholar
• Cerne J, Stegel V, Gersak K, Novakovic S. KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer 2012; 12:105-111; PMID:22436609; http://dx.doi.org/10.1186/1471-2407-12-105
   PubMed Web of Science ®Google Scholar
• Salzman DW, Weidhaas JB. miRNAs in the spotlight: Making ‘silent’ mutations speak up. Nat Med 2011; 17:934-935; PMID:21818091; http://dx.doi.org/10.1038/nm0811-934
   PubMed Web of Science ®Google Scholar
• Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes MC. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435:646-651; PMID:15806097; http://dx.doi.org/10.1038/nature03556
   PubMed Web of Science ®Google Scholar
• Soule H, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990; 50:6075-6086; PMID:1975513
   PubMed Web of Science ®Google Scholar
• Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30:256-268; PMID:12798140; http://dx.doi.org/10.1016/S1046-2023(03)00032-X
   PubMed Web of Science ®Google Scholar
• Sweasy J, Lang T, Starcevic D, Sun K, Lai C, Dimaio D, Dalal S. Expression of DNA polymerase {beta} cancer-associated variants in mouse cells results in cellular transformation. PNAS 2005; 102:14350-14355; PMID:16179390; http://dx.doi.org/10.1073/pnas.0505166102
   PubMed Web of Science ®Google Scholar
• Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS. A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. EMBO Mol Med 2012; 4:206-217; PMID:22307873; http://dx.doi.org/10.1002/emmm.201100200
   PubMed Web of Science ®Google Scholar